BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BioNTech SE reported its second quarter 2026 financial results showing decreased revenues primarily due to reduced demand for its COVID-19 vaccines, increased R&D and SG&A expenses driven by oncology pipeline advancements and acquisition integration, and a widened net loss. The company advanced its oncology pipeline with multiple pivotal trials ini…